Three Leading Animal Health Companies Join Hands to Launch World-Class Vaccine Joint Venture Targeting Foot-and-Mouth Disease in China
Shaanxi Meili Omni-Honesty Animal Health Co., Ltd., China’s world-class vaccine company targeting foot-and-mouth disease in swine, was launched on March 24th with a groundbreaking ceremony held at the Airport New City in Xi’an, capital city of Shaanxi Province. Meili Omni-Honesty is a joint venture between Boehringer Ingelheim, a leading global pharmaceutical company and the world’s second-largest animal health company, Beijing KangMu Omni-Honesty Animal Health Products Co., Ltd. (KMOH), and China Agricultural Vet. Bio. Science and Technology Co., Ltd.(ZNWT). The total investment amounts to 840 million yuan (around €108 million). The venture will focus on research, development and manufacture of vaccines against foot-and-mouth disease on a site that will answer the latest BSL3+ biosafety standards. Production is expected to start in 2021. (The venture is subject to regulatory approval.)
“China plays a key role in Boehringer Ingelheim’s global business. With the establishment of Meili Omni-Honesty, we will bring world-class vaccine technology to China and join hands with our partners to foster local R&D and production so as to serve the Chinese market. It again demonstrates our commitment of being ‘in China, for China’,” shared Hubertus von Baumbach, Chairman of the Board of Managing Directors at Boehringer Ingelheim. “Over a thousand years ago, the ancient Silk Road connected Xi’an to Lyon. Today, Lyon, where Boehringer Ingelheim’s R&D hub for state-of-the-art technology in vaccines against foot-and-mouth disease is located, and Xi’an are connected again in the Meili Omni-Honesty project” According to Hubertus von Baumbach, Boehringer Ingelheim, as a global leader in animal health, hopes to help facilitate the growth of China’s animal health industry and develop its talents. The company is committed to contributing to the country’s animal health and food safety sectors.
In January 2017, with the acquisition of Merial, Boehringer Ingelheim further strengthened its position as a global leader in animal health. The three companies involved in the Meili Omni-Honesty project all bring unique expertise to help fight foot-and-mouth disease in China. Boehringer Ingelheim is the world’s leader in Veterinary Public Health, with state-of-the-art technology for vaccines against foot-and-mouth disease. ZNWT is approved by the Ministry of Agriculture to produce the full set of vaccines against foot-and-mouth disease. KMOH has extensive market channels across the country, as well as rich marketing experience.
Foot-and-mouth disease is a highly infectious disease that currently threatens and hinders the development of the Chinese livestock industry. It poses a big threat to the health of cloven-hoofed animals such as pigs, cattle and sheep. China National Foot and Mouth Disease Reference Laboratory under Lanzhou Veterinary Research Institute is the authorized agency to identify and confirm foot-and-mouth disease. Lanzhou Veterinary Research Institute is also an authorized research institute in China to develop vaccines against foot-and-mouth virus.
“ZNWT is relying on Lanzhou Veterinary Research Institute for technical support and is playing a leading role in prevention and control of animal diseases in China,” said Zhang Yunde, Chairman and General Manager of ZNWT. He concluded that the collaboration with Boehringer Ingelheim and KMOH will lead to unprecedented advance and breakthrough in disease prevention and control, vaccine technology and market growth. The new joint venture will tap into advantages and cooperation of the three companies to shape the swine vaccine market for foot-and-mouth disease in China.
“Foot-and-mouth disease in swine is an epidemic that has a significant impact on animal husbandry and food safety. It is highly contagious and has a high mortality rate. The market is in urgent need of vaccines featuring the world’s top-level technology,” said Yuan Ximin, Chairman of Shaanxi Meili Omni-Honesty Animal Health Co., Ltd. “I believe this project will drive transformation and upgrading of China’s animal vaccine industry, and it will also help improve economic benefits for Chinese farmers.” Yuan also shared that the Airport New City in Xi’an was chosen for the Meili Omni-Honesty project because of its policy and location advantages. The Shaanxi Pilot Free Trade Zone was formally approved in 2017, bringing new opportunities for the Airport New City. This is the only free trade zone approved in northwest China, and the core area to lead Xi’an growth. The Meili Omni-Honesty project will promote development of the bio-pharmaceutical industry chain at the Airport New City and attract more healthcare players to settle there.
Please click on the link for ‘Notes to Editors’ and ‘References’: https://www.boehringer-ingelheim.com/press-release/joint-venture-targeting-foot-and-mouth-disease-china
Media Contact - Animal Health
+49 6132 – 77 2356
Fax: +49 6132 – 77 6601
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Abu Dhabi to Host Interfaith Alliance For Safer Communities: Child Dignity in the Digital World Forum on 19 November17.11.2018 16:40 | Tiedote
Held under the patronage of His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, the UAE will host the first edition of the Interfaith Alliance For Safer Communities Forum on November 19-20 in recognition of the country’s leading role in promoting tolerance and interfaith dialogue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181117005008/en/ His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces (Photo: AETOSWire) The forum will host 450 guests including religious leaders, NGOs and heads of industry to discuss ongoing social challenges and develop comprehensive solutions for protecting youth from cybercrime. The Interfaith Alliance For Safer Communities Forum is an expansion of the Child Dignity in the Digital World Congress which was held in October 2017 in the Vatican, an
Philip Morris International and Dorna Switch Gears in Quest for a World without Tobacco Smoke17.11.2018 14:00 | Tiedote
Philip Morris International Inc. (PMI) (NYSE:PM) and Dorna Sports S.L., the commercial rights holder for the world FIM MotoGP Championships, have extended their partnership until the end of 2021. The two organizations have collaborated successfully for 26 years. As of 2019, the partnership will focus on advancing the cause of a smoke-free world. More than 1 billion people smoke today and, according to the World Health Organization, will continue to smoke in the near future. PMI has committed to transform its business and encourage all men and women who would otherwise continue smoking to replace cigarettes with better alternatives as soon as possible. With around 350 million MotoGP fans worldwide, MotoGP can play a significant role in positively impacting the lives of people who smoke and those around them. “The best choice for consumers concerned about the health risks of smoking is to quit tobacco and nicotine altogether. Today, however, technology, science and innovation provide a r
Schlumberger Announces Fourth-Quarter and Full-Year 2018 Results Conference Call16.11.2018 21:00 | Tiedote
Schlumberger Limited (NYSE:SLB) will hold a conference call on January 18, 2019 to discuss the results for the fourth quarter and full year ending December 31, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 18, 2019, and can be accessed by dialing +1 (800)
Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 17:33 | Tiedote
Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W
Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 16:55 | Tiedote
Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’
Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 16:15 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme